An update from Tivic Health Systems ( (TIVC) ) is now available.
On April 10, 2025, Tivic Health Systems announced that it has regained compliance with Nasdaq’s Minimum Bid Price Requirement, ensuring its continued listing on the Nasdaq Capital Market. This follows a series of events where the company faced potential delisting due to its stock price falling below $1.00 for 33 consecutive days in 2024. After implementing a reverse stock split and meeting the necessary requirements, Nasdaq confirmed compliance, allowing Tivic Health to maintain its market position and providing stability for its stakeholders.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
Tivic Health Systems’ stock faces challenges primarily due to weak financial performance characterized by declining revenues and consistent losses. Despite strategic transformations and potential growth in pharmaceuticals, the current financial health and bearish technical indicators significantly impact the stock’s attractiveness. The company’s efforts to diversify and strategic acquisitions offer future potential but are currently overshadowed by the need for improved operational efficiency and profitability.
To see Spark’s full report on TIVC stock, click here.
More about Tivic Health Systems
Tivic Health Systems, Inc. is a diversified therapeutics company focusing on harnessing the immune and autonomic nervous systems to combat diseases and restore health. The company develops non-invasive medical devices for the vagus nerve and has a biopharma division with a lead product, Entolimod, in late-stage studies for acute radiation syndrome. Tivic Health also offers an FDA-approved over-the-counter device, ClearUP, for sinus pain and pressure.
YTD Price Performance: -18.03%
Average Trading Volume: 1,254,154
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.99M
For an in-depth examination of TIVC stock, go to TipRanks’ Stock Analysis page.